



Press release

GRIPonMASH screens first patient and reports strong first-year results

Breaking milestones reached in project aiming to improve prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH)

Utrecht, The Netherlands, 17-12-2024: GRIPonMASH, a consortium dedicated to bring about a transformational change in the detection and diagnosis of MASH patients at different levels of health care management, completed its first year of research. GRIPonMASH focuses on designing and optimizing a sustainable and scalable GRIPonMASH diagnostic platform.

First patient successfully screened

A significant milestone achieved during the first year was the inclusion of the first patient in the study in Rotterdam. Other sites followed suit in including patients for the screening in the study. This will allow the consortium to set-up a biobank and data science platform to test both existing and novel biomarkers, and to leverage artificial intelligence-based technology to improve the detection of MASH. In the coming year all 12 hospitals/research institutes in the consortium will start screening patients to reach the target of 10.000 patients screened as stated in the agreement.

Pilot diagnostic platform

The first year also saw the development of the GRIPonMASH diagnostic platform by ways of a pilot study conducted at Amsterdam UMC. When tested sufficiently, the platform will be rolled out across all 12 participating clinical sites.

Lifestyle assessment

Another key milestone was developing and selecting questionnaires to explore lifestyle habits linked to metabolic dysfunction-associated steatotic liver disease (MASLD). The healthcare professionals at the 12 GRIPonMASH locations also received training in accurately capturing dietary information. The findings will provide valuable guidance for healthcare professionals, researchers, and patients in developing personalized lifestyle approaches.

Communication, dissemination and education

During the first year of the GRIPonMASH project, the groundwork was established for a solid communication, dissemination, and educational strategy. A key insight highlighted the critical importance of raising awareness about MASH among primary healthcare providers. To address this need, an awareness campaign was created, supported by concise educational modules that will be easily accessible on the project website.

NOTE FOR THE EDITOR, NOT FOR PUBLICATION

About GRIPonMASH

GRIPonMASH is a consortium founded by Julius Clinical (CRO, Zeist, NL) and UMCU (University Medical Center Utrecht) consisting of 27 involved parties dedicated to bring about a transformational change in the detection and diagnosis of MASH patients. The four year project is funded by the Innovative Health Initiative Joint Undertaking (IHI) which is funded jointly by the European Union (represented by the European Commission) and the life science industries (represented by COCIR, EFPIA / Vaccines Europe, EuropaBio, MedTech Europe, Vaccines Europe and Merckodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV). The aim is to achieve better information, diagnosis and lifestyle advice on MASH in order to increase the number of people diagnosed and aware of the lifestyle changes needed and thus decreasing the number of people with MASH and liver cancer.

The project is coordinated by the UMC Utrecht and Julius Clinical in the Netherlands.

Learn more about GRIPonMASH and contributing partners through www.griponmash.eu

For questions, please contact:

Project Management Office

info@griponmash.eu

The GRIPonMASH project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe and Merckodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

www.ih.europa.eu

